ICD-10 Specific code F90: Hyperkinetic disorders
Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
Translations
| Language | Translation |
|---|---|
English
|
Hyperkinetic disorders |
French
|
Troubles hyperkinétiques |
Hierarchical position
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Mental and behavioural disorders | |
| 2 | F90-F98 | Behavioural and emotional disorders with onset usually occurring in childhood and adolescence | |
| 3 | F90 | Hyperkinetic disorders |
Contents
| Code | Title | |
|---|---|---|
| F90.0 | Disturbance of activity and attention | |
| F90.1 | Hyperkinetic conduct disorder | |
| F90.8 | Other hyperkinetic disorders | |
| F90.9 | Hyperkinetic disorder, unspecified |
Indicated medicines
| Active Ingredient |
|---|
|
Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters. |
|
Clonidine has been shown to have both central and peripheral sites of action. With long-term treatment clonidine reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone. |
|
Guanfacine is a selective alpha2A-adrenergic receptor agonist in that it has 15-20 times higher affinity for this receptor subtype than for the alpha2B or alpha2C subtypes. Guanfacine is a non-stimulant. The mode of action of guanfacine in ADHD is not fully established. |
|
Methylphenidate is a CNS stimulant (psychostimulant) with more pronounced effects on central than on motor activities. The mechanism of action in humans is not fully understood; however, it is thought that the effect is due to inhibition of dopamine reuptake in the striatum without triggering a release of dopamine. |
|
Tiapride is an atypical neuroleptic which exhibits selectivity in in-vitro studies for D2 and D3 dopamine subtype receptors without any affinity for subtype receptors of the principal central neurotransmitters (including serotonin, noradrenaline and histamine). |